D. Dodwell

发表

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

P. Neven, V. Semiglazov, S. Johnston, 2008, Breast Cancer Research and Treatment.

Shared understanding in psychiatrist-patient communication: association with treatment adherence in schizophrenia.

P. Healey, S. Bremner, R. McCabe, 2013, Patient education and counseling.

POSNOC: A Randomised Trial Looking at Axillary Treatment in Women with One or Two Sentinel Nodes with Macrometastases.

D. Dodwell, A. Goyal, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Learning from disaster.

D. Dodwell, D Dodwell, 1991, BMJ.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of self-ratings with informant-ratings of pre-morbid personality on two personality rating scales

D. Dodwell, 1988, Psychological Medicine.

Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours.

I. Ellis, P. Tan, E. Rakha, 2013, Breast.

Morbidity of tamoxifen-perceptions of patients and healthcare professionals.

J. Bishop, D. Dodwell, J. Adlard, 2002, Breast.

International Variation in Criteria for Internal Mammary Chain Radiotherapy

S. Darby, P. Mcgale, D. Dodwell, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

J. Bergh, R. Peto, R. Jagsi, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

D. Cameron, D. Dodwell, R. Bell, 2014, The Lancet. Oncology.

Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ.

G. Ball, S. Pinder, E. Sawyer, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A systematic review of methods to immobilise breast tissue during adjuvant breast irradiation

D. Dodwell, H. Probst, Christopher M. Bragg, 2014 .

Adjuvant radiotherapy after conservative surgery for breast cancer: is it always necessary?

D. Dodwell, J. Loncaster, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Denis Talbot, Sean McPhail, Jem Rashbass, 2016, The Lancet. Oncology.

Doing More With Less; Are There Some 'Easy Wins' in the Management of Early Breast Cancer?

D. Dodwell, R. Coleman, A. Richmond, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

Follow-up care of patients treated for breast cancer: a structured review.

D. Dodwell, H. Bekker, R. Collins, 2004, Cancer treatment reviews.

A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer.

D. Ash, D. Dodwell, D. Dodwell, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1.

D. Dodwell, N. Thatcher, H. Gurney, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747)

A. Howell, M. Dowsett, D. Cameron, 2012 .

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

A. Howell, M. Dowsett, P. Ellis, 2013, The Lancet. Oncology.

Long-Term Follow-Up of the Intergroup Exemestane Study.

P. Lønning, L. Fallowfield, R. Paridaens, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

D. Dodwell, R. Coleman, R. Wakefield, 2010, Breast Cancer Research and Treatment.

Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

H. Earl, J. Peto, J. Yarnold, 2007, Journal of the National Cancer Institute.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2017, The Lancet. Oncology.

Optimum anthracycline-based chemotherapy for early breast cancer.

D. Dodwell, J. Adlard, David Dodwell, 2001, The Lancet. Oncology.

Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.

M. Namer, D. Dodwell, C. Unger, 2001, Clinical breast cancer.

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.

I. Vergote, D. Dodwell, 2005, Cancer treatment reviews.

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.

M. Dowsett, J. Robertson, D. Dodwell, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Axillary conservation in early breast cancer

D. Dodwell, A. Goyal, 2015, The British journal of surgery.

Use of boost radiotherapy in oncoplastic breast-conserving surgery - a systematic review.

D. Dodwell, M. Schaverien, S. Stallard, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)

D. Cameron, D. Dodwell, C. Davies, 2010 .

Breast-cancer adjuvant therapy with zoledronic acid.

W. Gregory, D. Cameron, D. Dodwell, 2011, The New England journal of medicine.

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial

D. Dodwell, Janet E Brown, R. Coleman, 2012, Journal of bone oncology.

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

D. Dodwell, Janet E Brown, R. Coleman, 2008, Clinical Cancer Research.

Kalevala or Keats: poetic traditions as a model for multidisciplinary miscommunication and team splitting.

D. Dodwell, 2008, Journal of psychiatric and mental health nursing.

Cardiac morbidity of post-operative adjuvant radiotherapy for breast cancer. A review.

D. Dodwell, A. Langlands, 1994, Australasian radiology.

Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project

J. Dewar, D. Dodwell, K. Clements, 2007, British Journal of Cancer.

Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study

F. Climent, I. Ellis, P. Tan, 2014, British Journal of Cancer.

Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ

S. Pinder, M. Wallis, L. Fallowfield, 2013 .

Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer

D. Dodwell, G. Velikova, T. Perren, 2009, Cancer Chemotherapy and Pharmacology.

Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.

S. Johnston, D. Dodwell, J. Bliss, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

D. Cameron, D. Dodwell, R. Bell, 2011, Breast Cancer Research and Treatment.

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

D. Cameron, D. Dodwell, A. Wardley, 2005, British Journal of Cancer.

Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study

D. Cameron, D. Dodwell, R. Bell, 2016, Journal of bone oncology.

The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project.

S. Pinder, E. Sawyer, A. Evans, 2016, Breast.

Cardiac dose from tangential breast cancer radiotherapy in the year 2006.

S. Darby, P. Mcgale, D. Dodwell, 2008, International journal of radiation oncology, biology, physics.

Issues in the Management of Occult Neoplasia in Breast Reduction Surgery

D. Dodwell, A. Hanby, P. Turton, 2012, The breast journal.

The Systemic Treatment of Bone Metastases

A. Howell, D. Dodwell, 1991 .

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.

W. Gregory, R. Gomis, F. Rojo, 2017, The Lancet. Oncology.

Treating bony metastases.

A. Howell, D. Dodwell, 1991, BMJ.

New endocrine approaches to breast cancer.

A. Howell, D. Dodwell, H. Anderson, 1990, Bailliere's clinical endocrinology and metabolism.

Aromatase inhibitors and musculoskeletal symptoms.

D. Dodwell, S. Khanduri, 2008, Breast.

Dose intensity in cancer chemotherapy.

D. Dodwell, N. Thatcher, H. Gurney, 1990, British Journal of Cancer.

Theheterogeneity ofsocial outcomefollowing head injury

D. Dodwell, 1988 .

Assessment of palliative chemotherapy: a step beyond response.

D. Ash, D. Dodwell, A. Rathmell, 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

Psychiatric discharge summaries: what do general practitioners want?

D. Dodwell, Jaco Serfontein, Purvy Patel, 2011, Mental health in family medicine.

The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases

A. Howell, D. Dodwell, R. Coleman, 1991, Calcified Tissue International.

D. Dodwell, J. Joffe, W. Jones, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Malignant bone resorption: cellular and biochemical mechanisms.

D. Dodwell, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.

C. Wilson, D. Cameron, D. Dodwell, 2018, European journal of cancer.

Abstract GS4-02: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials

T. Whelan, T. Kühn, R. Gray, 2019, General Session Abstracts.

Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.

S. Johnston, D. Dodwell, A. Wardley, 2006, Breast.

Time to response: comparison of fulvestrant and oral endocrine agents.

D. Dodwell, J. Pippen, 2006, Clinical breast cancer.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

Neoadjuvant chemotherapy for early breast cancer - Author's reply.

R. Gray, P. Mcgale, D. Dodwell, 2018, The Lancet. Oncology.

The potential for proteinase inhibition in cancer treatment.

A. Howell, D. Dodwell, 1993, Cancer treatment reviews.

Adjuvant treatment for breast cancer

D. Dodwell, M. Flatley, 2019, Surgery (Oxford).

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.

L. Zelek, M. Namer, A. Lluch, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom

D. Dodwell, R. Coleman, J. Horsman, 2005, British Journal of Cancer.

Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study

D. Dodwell, Janet E Brown, R. Coleman, 2008 .

HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit.

D. Dodwell, C. Palmieri, O. Gojis, 2010 .

Tamoxifen as an Agonist for Metastatic Breast Cancer

A. Howell, D. Dodwell, H. Anderson, 1990 .

Implications of ejection fraction value for trastuzumab

D. Dodwell, T. Perren, D. Schlosshan, 2006, BMJ : British Medical Journal.

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study

D. Dodwell, S. M. Crawford, T. Perren, 2004, British Journal of Cancer.

Eligibility for Partial Breast Radiotherapy in England.

S. Darby, P. Mcgale, C. Taylor, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.

A. Howell, D. Dodwell, A. Seymour, 1992, British Journal of Cancer.

Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.

D. Dodwell, D. Dodwell, K. Clements, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Chemotherapy for Hodgkin’s Disease and Aggressive Non-Hodgkin’s Lymphoma

J. Radford, D. Dodwell, E. Campos, 1992, Drugs.

Skin telangiectasia: the influence of radiation dose delivery parameters in the conservative management of early breast cancer.

D. Dodwell, A. Eastwood, G. Gerrard, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study

P. Lønning, L. Fallowfield, L. Gibson, 2003, BMJ : British Medical Journal.

What constitutes intensive treatment?

D. Dodwell, 2001, British Journal of Psychiatry.

The NHS breast screening programme.

D. Dodwell, M. Mcmahon, N. Sharma, 2013, British journal of hospital medicine.

Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice.

M. Reed, D. Dodwell, R. Coleman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Management of Malignant Hypercalcaemia

D. Dodwell, G. Gerrard, J. Watters, 1996, Drugs.

Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects.

W. Gregory, D. Cameron, D. Dodwell, 2012 .

A translation of "L´Elettroshock" by Cerletti & Bini, with an introduction

D. Dodwell, A. Metastasio, 2013 .

Proteinase Inhibitors in Malignancy: Therapeutic Promise or Another White Elephant?

D. Dodwell, 1993, Journal of the Royal Society of Medicine.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

J. Baselga, B. Leyland-Jones, V. Semiglazov, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

R. Gelber, D. Cameron, M. Piccart-Gebhart, 2013, The Lancet. Oncology.

Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study

S. Darby, D. Dodwell, O. Kearins, 2020, BMJ.

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.

S. Pinder, M. Wallis, A. Evans, 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

A. Tres, J. Mayordomo, N. Ibrahim, 2011, The oncologist.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

G. Ball, S. Lakhani, S. Pinder, 2018, European journal of cancer.

Addressing overtreatment of screen detected DCIS; the LORIS trial.

S. Pinder, M. Wallis, D. Rea, 2015, European journal of cancer.

Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis.

J. Radford, W. Ryder, D. Dodwell, 1992, European journal of cancer.

Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK.

D. Dodwell, R. Coleman, O. Din, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

High dose, dose-intensive chemotherapy with Doxorubicin and Cyclophosphamide for the treatment of advanced breast cancer

A. Howell, D. Dodwell, A. Seymour, 1992 .

Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.

D. Dodwell, N. Thatcher, H. Gurney, 1991, European journal of cancer.

Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial.

S. Johnston, D. Dodwell, G. Velikova, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

The causes and treatment of bone loss associated with carcinoma of the breast.

E. McCloskey, D. Dodwell, R. Coleman, 2005, Cancer treatment reviews.

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

C. Wilson, W. Gregory, R. Gomis, 2018, Journal of bone oncology.

Treatment of a pancreatic tumour secreting parathyroid hormone related protein.

D. Dodwell, H. Gurney, H. Scarffe, 1990, BMJ.

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

R E Coleman, D. Cameron, D. Dodwell, 2010, British Journal of Cancer.

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer.

A. Howell, D. Dodwell, H. Anderson, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Are prescriptions consistent with diagnosis? A survey of adult psychiatry discharge letters

D. Dodwell, Collins Esiwe, 2008 .

A randomised controlled trial of two programmes of shoulder exercise following axillary node dissection for invasive breast cancer

D. Dodwell, K. Horgan, A. Scally, 2008 .

Abstract P2-14-01: Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors – a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007)

A. Howell, M. Dowsett, M. Piccart, 2012 .

The Effect of Clozapine on Self-reported Duration of Sleep and Its Interaction With 23 Other Medications

E. Fernandez-Egea, S. Mitchell, D. Dodwell, 2021, Journal of clinical psychopharmacology.

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

R. Coombes, M. Climent, U. Dafni, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The SMALL Trial: A Big Change for Small Breast Cancers.

S. Pinder, D. Rea, S. Taylor-Phillips, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS).

Mary E Booth, D. Dodwell, O. Kearins, 2014, Breast.

Changes in distress of psychiatric in-patients after the changeover of junior psychiatric trainees as a function of attachment style: A pilot study

D. Dodwell, Toral Thomas, Z. Iqbal, 2012 .

The heterogeneity of social outcome following head injury.

D. Dodwell, 1988, Journal of neurology, neurosurgery, and psychiatry.

Lytic bone metastases after APD in breast carcinoma: Authors' reply

A. Howell, D. Dodwell, 1988 .

An evaluation of the accuracy of semi-permanent skin marks for breast cancer irradiation

D. Dodwell, H. Probst, J. Gray, 2006 .

Adjuvant thoracic radiation in small cell lung cancer.

D. Dodwell, J. Gildersleve, 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial

Christopher Poole, Helena M. Earl, H. Earl, 2007 .

Waiting times for radiotherapy after breast-conserving surgery and the association with survival: a path analysis.

D. Forman, D. Dodwell, M. Gilthorpe, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Brachytherapy boost to the tumour bed in high risk patients after limited surgery for breast cancer.

D. Ash, D. Dodwell, H. C. Ulutin, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial

S. Pinder, M. Wallis, D. Rea, 2017, Annals of Surgical Oncology.

Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.

D. Dodwell, D. Williamson, 2008, Cancer treatment reviews.

A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.

M. Dowsett, J. Robertson, D. Dodwell, 1997, Oncology.

Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.

A. Howell, D. Dodwell, J. Ford, 1990, British Journal of Cancer.

Immediate and delayed autologous abdominal microvascular flap breast reconstruction in patients receiving adjuvant, neoadjuvant or no radiotherapy: a meta‐analysis of clinical and quality‐of‐life outcomes

D. Dodwell, D. Dodwell, Z. Winters, 2019, BJS open.

Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.

A. Howell, D. Dodwell, D. Dodwell, 1991, European journal of cancer.

Multidisciplinary team working: the emperor without clothes?

Sarah Thornton, D. Dodwell, 2012, British journal of hospital medicine.

The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials reporting changes in bone mineral density as a surrogate. The AZURE trial

C. Wilson, D. Cameron, D. Dodwell, 2019 .

5155 POSTER Reduction in Fractures Following Adjuvant Zoledronic Acid in Stage ll/lll Breast Cancer – the AZURE Trial (BIG 01/04)

D. Cameron, D. Dodwell, C. Davies, 2011 .

Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery

D. Forman, P. Pisani, D. Dodwell, 2004, British Journal of Cancer.

Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.

D. Dodwell, N. Thatcher, H. Gurney, 1993, Annals of Oncology.

Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases.

A. Howell, L. Dirix, A. V. van Oosterom, 1991, European Journal of Cancer.

Residual disease after mastectomy.

D. Dodwell, N. Bundred, R. Cutress, 2020, The Lancet. Oncology.

Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.

A. Howell, D. Dodwell, P. Daley-Yates, 1992, Postgraduate medical journal.

re: Review Article: Pathogenesis of bone metastases in breast cancer

D. Dodwell, 1993 .

Counterpoint: Does Mastectomy Reduce Overall Survival in Early Stage Breast Cancer?

D. Dodwell, D. Wheatley, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Timing of sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant chemotherapy.

D. Dodwell, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

P. Lønning, J. Forbes, R. Coombes, 2007, The Lancet.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

D. Cameron, D. Dodwell, R. Bell, 2014, The Lancet. Oncology.

Personal therapeutic relationship does matter

D. Dodwell, 2012 .

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

D. Dodwell, R. Bell, M. Keane, 2018, Journal of bone oncology.